AI-Based Spirometers Market

AI-Based Spirometers Market Outlook 2025 to 2035

The global AI-based spirometers market is expected to reach USD 536.9 Million by 2035, up from USD 89.7 Million in 2025. During the forecast period 2025 to 2035, the industry is projected to expand at a CAGR of 19.6%.

The increased interest in early prevention of respiratory illnesses combined with an increase in the number of cases of asthma, COPD, and post-COVID pulmonary complications is driving the demand of AI-based spirometers. These gadgets are more accurate, predictive and can integrate with telehealth systems, enabling remote monitoring and individual care.

In addition, growing the use of AI-enabled spirometry tools in hospitals, clinics, and home care setting, as well as improving affordability and AI-based data analytics, are stimulating high market expansion of AI-enabled spirometry solutions on a global scale.

Quick Stats for AI-Based Spirometers Market

• Industry Value (2025): USD 89.7 Million
• Projected Value (2035): USD 536.9 Million
• Forecast CAGR (2025 to 2035): 19.6%
• Leading Segment (2025): Handheld Spirometers (33.2% Market Share)
• Fastest Growing Country (2025-2035): India (21.1% CAGR)
• Top Key Players: COSMED srl, FUKUDA SANGYO CO., Geratherm Medical AG, Hill-Rom Holdings, ndd Medical Technologies, Schiller AG, Sibelmed, Teleflex Incorporated, Vitalograph, and Vyaire Medical Inc.

What are the drivers of the AI-Based Spirometers Market?

The AI-based spirometers market is projected to grow as healthcare providers and patients are more than willing to have access to the accurate and real-time respiratory monitoring solutions. Adoption is being driven by increasing prevalence of asthma, COPD and other chronic lung diseases as well as increased awareness of early diagnosis. The implementation of AI helps to improve the precision of diagnostic, conduct predictive analysis, and plan a treatment course individually.

The new demands in the field of portable, connected spirometry devices are also increased by the rapid transition to telemedicine and home-based care following the COVID-19 pandemic. Also, the improvements in cloud-based analytics, smartphone integration, and pricing are also making AI-based spirometers more accessible and lead to the large-scale adoption of AI use in hospitals, clinics, and homecare environments all over the world.

What are the regional trends of the AI-Based Spirometers Market?

There are regional differences in the AI-based spirometer market that are dependent on the healthcare infrastructure, uptake of technology, and prevalence of disease.

• In terms of high COPD and asthma rates, developed healthcare systems, and AI integration in digital health, North America is the top demand.
• Europe comes next with conducive reimbursement policies and emphasis on early diagnosis.
• Asia-Pacific is developing fast with China, India, and Japan leading the pack, with the increase of respiratory diseases, urban pollution, and telehealth.
• Latin America is slowly following suit with AI spirometry with hospital upgrades, with the Middle East & Africa becoming more and more uptake with digital health efforts and government funding.

What are the challenges and restraining factors of the AI-Based Spirometers Market?

There are threats to the AI-based spirometers market that negate its possible adoption. The expense of the devices and inadequate reimbursement policy constraints access especially in developing countries. There are also data privacy and security challenges to AI-driven analytics, which are obstacles to adoption.

Combination with other healthcare IT systems may be complicated, which slows the implementation aspect among hospitals and clinics. Low-income markets have a lower level of awareness of AI-based respiratory diagnostics, and a poor infrastructure decreases adoption.

Also, the accuracy of the devices might differ when used in the home by the patients hence reliability is an issue. The presence of regulatory obstacles and the necessity to make a clinical validation also limits market growth in the world.

Country-Wise Insights

United States leads with strong AI spirometer adoption growth

The United States is the biggest market of AI-based spirometer devices, which are facilitated by developed healthcare systems, elevated spending on healthcare, and robust adoption of AI in healthcare diagnostics. Asthma and COPD rates are extremely high in the country, and millions of patients should be monitored regarding their lung functions on a regular basis.

The usage of telemedicine was soaring after the COVID and made the need in portable and connected spirometry devices even more pressing. High concentration of major medtech firms and drive towards digital health innovation are positive factors that boost growth. There is a gradual expansion of reimbursement models to support AI-based diagnostics to increase access and stimulate the use of AI-based spirometers on a large scale by hospitals, clinics, and homecare providers.

Germany advances AI spirometers through robust healthcare infrastructure

The use of AI-based spirometers in Germany is a central European location due to the developed healthcare systems, favorable research environments, and governmental support of digital health change. The nation is also highly concerned with early respiratory infections and proactive treatment, and the AI-based spirometry solutions align with it.

The increasing number of elderly and high rates of chronic respiratory diseases are additional market demand factors. The usage of AI in medical devices in Germany is supported by strong regulatory frameworks and asymmetry of telehealth platforms. Hospital-university-technology partnerships are a source of innovation, and reimbursement and government funding promotes the implementation of connected diagnostic solutions in healthcare environments.

China rapidly expands AI spirometer market amid pollution challenges

AI-based spirometers are rapidly developing in China due to the increase in cases of asthma, COPD, and respiratory complications related to urban air pollution. The large size and growing healthcare investments in the country make the country a prime growth market. Innovation in AI applications in healthcare and other digital health methods supported by the government will lead to quicker introduction of AI-based diagnostic applications.

The growing telemedicine environment and increasing popularity of devices compatible with smartphones are reinforcing the utilization of portable spirometers within the hospital and home environment. As the cost of AI-based spirometry equipment drops and local production of AI-based medical devices occur, China is set to provide one of the most lucrative markets in the worldwide AI-driven spirometry area.

Category-Wise Analysis

Portable AI devices enable real-time lung monitoring globally

The market is dominated by handheld AI-based spirometers that are portable, easy to use and increasingly used in clinical and home care practices. These types of devices provide real-time functionality to analyze respiratory functions with AI-based data analysis, which is extremely useful when it comes to patient self-monitoring and telehealth.

The demand for at-home lung health monitoring has also increased after COVID. The fact that they are cheap as compared to the conventional lab-based spirometry systems promotes their usage in developing nations. Smartphone and cloud integration improves the sharing of data with physicians, which allows personalized care. This ease, precision, and availability of handheld spirometers make them the most popular segment in the world.

AI spirometers aid early detection, monitoring, personalized COPD care

COPD represents the most significant disease application market in the AI-based spirometers market, as the archetype is becoming more prevalent in the world, especially in the aging population and smoking at-risk groups. The critical requirement of continuous disease management is met by AI-enhanced spirometry, which allows detecting the disease early, monitoring it accurately, and providing a personalized treatment plan.

As COPD is one of the major causes of death among the global population, clinicians are investing in superior diagnostic equipment. Predictive analytics based on AI help to assist clinicians to detect exacerbations at an earlier stage, decrease hospitalization and treatment expenses. The increase of awareness, the governmental efforts concerning the chronic disease management, and the introduction of telehealth services make the usage of AI spirometers in COPD treatment highly justified.

Hospitals use AI spirometers for precise patient management

Hospitals are the primary end-user market of AI-based spirometers, as they deal with the proper testing of the pulmonary functioning and treating a high number of patients. Hospitals need highly accurate equipment that can be easily connected to electronic medical record (EHR) and AI-driven analytics to make clinical decisions.

The AI-enhanced spirometry results in increased reliability of diagnoses, workflow efficiency, and patient outcomes and are of great demand in hospitals. The accessibility of talented professionals, high-quality infrastructure, and good reimbursement policies also facilitate the adoption of hospitals. Moreover, further, hospitals also apply AI spirometers to monitor respiration after surgery, chronic diseases, and prevention care and are consolidating their leadership in this market segment in the world.

Competitive Analysis

Key players in the AI-based spirometers market include COSMED srl, FUKUDA SANGYO CO., Geratherm Medical AG, Hill-Rom Holdings, ndd Medical Technologies, Schiller AG, Sibelmed, Teleflex Incorporated, Vitalograph, Vyaire Medical Inc.

The market of AI-based spirometers is very competitive with innovation, use of AI, and easy to use designs. The major players, including Philips, MIR, NDD Medical, and Cosmed, are concerned with portable, handheld, and connected hospital, clinic and homecare. Competitive approaches involve collaborations with medical practitioners and telehealth solutions and research institutions to improve adoption.

The differentiation comes through the AI-based predictive analytics, real-time monitoring, cloud data sharing, and smartphone integration. The developing economies are dependent on low-price equipment, whereas the developed markets use the latest technology to improve the accuracy of diagnostics. The presence and competitive positioning in the market are enhanced by e-commerce distribution, service support, and collaboration in the clinics worldwide.

Recent Development

• In March 2025, AstraZeneca collaborated with ArtiQ to introduce AI into home spirometry to allow patients to do lung function tests in the house with AI analysis assistance. This partnership will enhance patient interaction and remote data monitoring.
• In November 2024, NDD Medical Technologies introduced the EasyOne Sky handheld spirometer, which has real-time AI interpretation and is connected to the cloud to monitor patients remotely. This device has the benefit of improving the accuracy of diagnosis as well as facilitating telehealth.

Fact.MR has provided detailed information about the price points of key manufacturers of AI-Based Spirometers Market positioned across regions, sales growth, production capacity, and speculative technological expansion, in the recently published report.

Methodology and Industry Tracking Approach

The AI smart spirometers market research paper utilized both primary research and secondary research to provide valid information. Primary research was done in 12 countries (2,800 healthcare professionals, patients, hospitals and clinics) survey and interview of 2,800 participants (60% of end-users and 40% of manufacturers, distributors, and providers of technology).

The survey focused on adoption trends, disease applications, device preferences, pricing, and integration with the digital health platforms during the period between September 2024 and August 2025. Secondary data analyzed firm reports, product releases, regulatory books, medical journals, and adoption of telemedicine statistics. The regression analysis, trend extrapolation, and scenario modeling used in forecasting gave the opportunity to make correct estimations of the market size, growth, and segmental trends at the global level.

With Fact.MR monitoring consumer behavior, product efficacy, industry trends, and market opportunities since 2018, this report is becoming an authoritative source of information that stakeholders can rely on.